ANKUR DRUGS AND PHARMA LIMITED

Registered Office: 20th Floor, Lotus Business Park, Off. Andheri Link Road, Andheri (West), Mumbai- 400 053

(Rs. lakh)

Sr. No.	Particulars	Quarter ended on 31.03.2011 (Un-audited)	Quarter ended on 31.03.2010 (Un-audited)	Year ended on 31.03.2011 (Un-audited)	Year ended on 31.03.2010 (Audited)
1	Net Sales/Income from Operations	12,123.82	26,142.50	82,399.73	106,740.76
2	Other Income	19.12	44.86	81.02	198.98
3	Total Income	12,143.04	26,187.36	82,480.75	106,939.74
4	**Total Expenditure**				
	a) (Increase)/decrease in stock	4,630.45	(3,762.10)	3,961.96	(372.26)
	b) Materials Consumed	6,203.51	23,089.47	67,175.31	79,980.60
	c) Labour and Staff Cost	839.09	528.64	2,972.92	2,322.73
	d) Manufacturing, administrative & selling expenses	1,174.27	891.57	5,020.60	3,620.46
5	**PROFIT BEFORE DEPRECIATION, FINANCE COST AND TAX**	(704.28)	5,439.88	13,349.96	21,418.21
6	Depreciation	2,186.38	901.25	6,080.60	2,663.98
7	**PROFIT BEFORE FINANCE COST, EXCHANGE FLUCTUATION AND TAX**	(2,890.66)	4,538.63	7,269.36	18,754.23
8	a) Interest and Financial Charges	3,218.03	2,154.67	10,821.83	8,074.98
	b) Provision for Exchange difference on Foreign Currency Loans	(157.47)	(241.22)	(157.47)	(1,543.07)
	c) Provision for redemption on redemption of FCCBs	364.80	134.37	1,044.68	343.72
9	**PROFIT BEFORE EXCEPTIONAL ITEM AND TAX**	(6,316.07)	2,490.81	(4,439.68)	11,878.60
10	Add/(Less): Exceptional Item:				
	Provision for Dimniution in value of Investments	55.38	-	(20.63)	(121.43)
11	**PROFIT BEFORE TAX**	(6,371.45)	2,490.81	(4,419.05)	12,000.03
12	Provision for taxation				
	-Current Tax	(390.00)	425.00	-	1,705.36
	-Deferred tax/(assets)	2,093.90	900.00	2,093.90	1,201.40
	-Excess provision for income-tax for earlier year		-	-	475.51
13	**Net profit after tax (11-12)**	(8,075.35)	1,165.81	(6,512.95)	8,617.76
14	Paid-up Equity Share Capital	1,934.16	1,934.16	1,934.16	1,934.16
15	Reserves & Surplus (Excluding Revaluation Reserve)	-	-	-	33,794.03
16	Earning per share (Rs.)				
	-Basic	(41.75)	6.03	(33.67)	44.56
	-Diluted	(32.43)	5.28	(26.15)	30.33
17	Aggregate of Non-Promoter Shareholding				
	-Number of Shares	14,601,709	12,221,110	14,601,709	12,221,110
	-Percentage of Shareholding (%)	75.49	63.19	75.49	63.19
18.	Promoter and Promoter Goup Shareholding				
	a) Pledged/ Encumbered				
	- Number of Shares	3,773,000	3,683,000	3,773,000	3,683,000
	- Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	79.60	51.72	79.60	51.72
	- Percentage of Shares (as a % of the total share capital of the company)	19.51	19.04	19.51	19.04
	b) Non-encumbered				
	- Number of Shares	966,881	3,437,480	966,881	3,437,480
	- Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	20.40	48.28	20.40	48.28
	- Percentage of Shares (as a % of the total share capital of the company)	5.00	17.77	5.00	17.77

NOTES:

1. The above results were reviewed by the Audit Committee and approved by the Board of Directors of the company in their meeting held on 14th May, 2011
2. During the year, the company has provided foreign Exchange Loss/(Gains) at the end of the year on loans which represents exchange differences arising during the year on foreign currency borrowings including FCCBs
3. The promoters has pledged 37,73,000 Equity Shares of the Company as security for amount borrowed by the company.
4. Investor complaints received and disposed off during quarter ended March 21, 2011:

Complaints pending at the beginning of the quarter	Nil
Complaints received during the quarter	2
Disposal of complaints	1
Complaints lying unresolved at the end of the quarter	1

5. As the company operates in a single business segment viz: "Pharmaceuticals Formulations", in the context of Accounting Standard 17, disclosure of segment information is not applicable

For ANKUR DRUGS AND PHARMA LIMITED

PURNANDU JAIN
Chairman and Managing Director

Place : Mumbai.
Dated: 14th May, 2011.